Published in Radiology on September 11, 2006
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA (2015) 9.02
ESUR prostate MR guidelines 2012. Eur Radiol (2012) 8.86
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol (2008) 2.23
Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol (2011) 2.03
Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol (2013) 1.60
Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol (2008) 1.60
Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging (2013) 1.54
Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. Radiology (2009) 1.48
Prostate cancer: prediction of biochemical failure after external-beam radiation therapy--Kattan nomogram and endorectal MR imaging estimation of tumor volume. Radiology (2011) 1.44
A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds. Rev Sci Instrum (2009) 1.42
Multimodal wavelet embedding representation for data combination (MaWERiC): integrating magnetic resonance imaging and spectroscopy for prostate cancer detection. NMR Biomed (2011) 1.29
Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer. Urology (2012) 1.28
Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging (2013) 1.27
Current use of PSMA-PET in prostate cancer management. Nat Rev Urol (2016) 1.27
MR-guided prostate interventions. J Magn Reson Imaging (2008) 1.18
Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol (2009) 1.18
Semi-automatic deformable registration of prostate MR images to pathological slices. J Magn Reson Imaging (2010) 1.17
MR imaging of the prostate in clinical practice. MAGMA (2008) 1.15
Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology (2009) 1.14
Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. Radiology (2014) 1.13
Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol (2010) 1.12
The promise of dynamic contrast-enhanced imaging in radiation therapy. Semin Radiat Oncol (2011) 1.12
Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol (2012) 1.11
Tumor focality in prostate cancer: implications for focal therapy. Nat Rev Clin Oncol (2010) 1.09
Multidisciplinary functional MR imaging for prostate cancer. Korean J Radiol (2009) 1.04
Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol (2013) 1.02
Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol (2008) 1.02
Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol (2015) 0.97
UMMPerfusion: an open source software tool towards quantitative MRI perfusion analysis in clinical routine. J Digit Imaging (2013) 0.96
Decision support system for localizing prostate cancer based on multiparametric magnetic resonance imaging. Med Phys (2012) 0.96
Contrast-enhanced magnetic resonance imaging of the breast: the value of pharmacokinetic parameters derived from fast dynamic imaging during initial enhancement in classifying lesions. Eur Radiol (2008) 0.96
Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol (2008) 0.96
Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. Eur Radiol (2010) 0.94
The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int (2013) 0.94
Radiotherapy planning using MRI. Phys Med Biol (2015) 0.93
Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images. Proc Natl Acad Sci U S A (2015) 0.93
Multiparametric magnetic resonance imaging of the prostate: current concepts. Radiol Bras (2015) 0.92
Simulated required accuracy of image registration tools for targeting high-grade cancer components with prostate biopsies. Eur Radiol (2012) 0.92
Performance comparison of 1.5-T endorectal coil MRI with 3.0-T nonendorectal coil MRI in patients with prostate cancer. Acad Radiol (2015) 0.91
Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI. Int J Radiat Oncol Biol Phys (2010) 0.90
Potential of hybrid ¹⁸F-fluorocholine PET/MRI for prostate cancer imaging. Eur J Nucl Med Mol Imaging (2014) 0.88
Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging. Med Phys (2015) 0.88
PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. Contemp Clin Trials (2015) 0.87
Incremental learning with SVM for multimodal classification of prostatic adenocarcinoma. PLoS One (2014) 0.86
Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.86
Is it possible to model the risk of malignancy of focal abnormalities found at prostate multiparametric MRI? Eur Radiol (2012) 0.85
Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magn Reson Med (2009) 0.85
Multiparametric-MRI in diagnosis of prostate cancer. Indian J Urol (2015) 0.85
Multivariate modelling of prostate cancer combining magnetic resonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters. Eur Radiol (2015) 0.84
3 Tesla multiparametric MRI for GTV-definition of Dominant Intraprostatic Lesions in patients with Prostate Cancer--an interobserver variability study. Radiat Oncol (2013) 0.83
Prostate focused ultrasound focal therapy--imaging for the future. Nat Rev Clin Oncol (2012) 0.83
Functional and molecular imaging of localized and recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.83
Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy. Br J Radiol (2013) 0.82
Pros and cons of focal therapy for localised prostate cancer. Prostate Cancer (2011) 0.82
Integrating multiparametric prostate MRI into clinical practice. Cancer Imaging (2011) 0.81
Augmenting MRI-transrectal ultrasound-guided prostate biopsy with temporal ultrasound data: a clinical feasibility study. Int J Comput Assist Radiol Surg (2015) 0.81
Current role of multiparametric magnetic resonance imaging for prostate cancer. Quant Imaging Med Surg (2015) 0.80
Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI). Eur Radiol (2014) 0.80
Modalities for imaging of prostate cancer. Adv Urol (2010) 0.80
Transrectal contrast enhanced ultrasound for diagnosis of prostate cancer. World J Urol (2007) 0.79
Early experience in MRI-guided therapies of prostate cancer: HIFU, laser and photodynamic treatment. Cancer Imaging (2011) 0.78
Molecular research in urology 2014: update on PET/MR imaging of the prostate. Int J Mol Sci (2014) 0.78
Prostate MRI: access to and current practice of prostate MRI in the United States. J Am Coll Radiol (2014) 0.78
DW-MRI of the urogenital tract: applications in oncology. Cancer Imaging (2010) 0.77
Multiparametric MRI for localized prostate cancer: lesion detection and staging. Biomed Res Int (2014) 0.77
Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. Insights Imaging (2016) 0.76
Imaging and intervention in prostate cancer: Current perspectives and future trends. Indian J Radiol Imaging (2014) 0.76
Staging of prostatic carcinoma at 1.5-T MRI: correlation of a simplified MRI exam with whole-mount radical prostatectomy specimens. Br J Radiol (2016) 0.75
Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights. Can Urol Assoc J (2015) 0.75
Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy. Medicine (Baltimore) (2016) 0.75
Image-Guided High-Dose-Rate (HDR) Boost Localization Using MRI/MR Spectroscopy: A Correlation Study with Biopsy. Cureus (2016) 0.75
Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview. Int Sch Res Notices (2014) 0.75
MRI in prostate cancer. Iran Red Crescent Med J (2013) 0.75
Feasibility study of computed vs measured high b-value (1400 s/mm²) diffusion-weighted MR images of the prostate. World J Radiol (2014) 0.75
Quantitative effects of acquisition duration and temporal resolution on the measurement accuracy of prostate dynamic contrast-enhanced MRI data: a phantom study. MAGMA (2017) 0.75
Pathologic correlation of transperineal in-bore 3-Tesla magnetic resonance imaging-guided prostate biopsy samples with radical prostatectomy specimen. Abdom Radiol (2017) 0.75
Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer. World J Urol (2015) 0.75
MRI Based Prostate Cancer Detection with High-level Representation and Hierarchical Classification. Med Phys (2017) 0.75
Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer. Diagnostics (Basel) (2017) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol (2006) 8.78
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol (2011) 5.59
Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 4.63
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol (2009) 3.69
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol (2003) 3.52
Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology (2011) 3.04
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology (2011) 2.92
The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol (2009) 2.92
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol (2004) 2.82
MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol (2008) 2.77
MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol (2008) 2.76
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res (2007) 2.63
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology (2012) 2.47
Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology (2003) 2.31
Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology (2013) 2.19
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol (2006) 2.14
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
A case of abiraterone acetate withdrawal. Eur Urol (2013) 2.06
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02
General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled trial. Addiction (2005) 1.97
Urinary markers in bladder cancer. Eur Urol (2007) 1.95
Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology (2007) 1.92
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol (2011) 1.90
The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol (2012) 1.88
A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) (2007) 1.87
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res (2004) 1.87
PET/CT: panacea, redundancy, or something in between? J Nucl Med (2004) 1.86
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology (2005) 1.82
Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol (2014) 1.77
Short echo time 1H-MRSI of the human brain at 3T with minimal chemical shift displacement errors using adiabatic refocusing pulses. Magn Reson Med (2008) 1.76
The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res (2007) 1.68
In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol (2011) 1.68
Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J Clin Oncol (2012) 1.66
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol (2011) 1.63
Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urol Oncol (2010) 1.63
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology (2004) 1.62
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J Magn Reson Imaging (2012) 1.57
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol (2006) 1.56
Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol (2009) 1.54
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol (2006) 1.51
Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol (2002) 1.50
Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol (2007) 1.49
Towards 1H-MRSI of the human brain at 7T with slice-selective adiabatic refocusing pulses. MAGMA (2008) 1.49
(19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol (2010) 1.49
The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol (2006) 1.45
Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging (2003) 1.45
Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol (2013) 1.44
Radiation effects in the rat spinal cord: evaluation with apparent diffusion coefficient versus T2 at serial MR imaging. Radiology (2008) 1.44
Familial aggregation of urothelial cell carcinoma. Int J Cancer (2002) 1.43
ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 1.43
Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer (2007) 1.42
Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. BJU Int (2011) 1.42
Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology (2007) 1.39